; (B) bandages; (C) alcohol swabs; (D) syringes; (E) needles; (F) gloves, masks, and other personal protective equipment; (G) cold storage equipment; and (H) other products the Secretary determines necessary for the administration of vaccines. (2) The term Secretary means the Secretary of Health and Human Services. 702. Vaccine and therapeutic development and procurement (a) Enhancing development, procurement and manufacturing capacity (1) In general The Secretary shall, as appropriate, award contracts, grants, and cooperative agreements, and, where otherwise allowed by law, enter into other transactions, for purposes of— (A) expanding and enhancing COVID–19 and SARS–CoV–2 vaccine and therapeutic development and research; (B) procurement of COVID–19 and SARS–CoV–2 vaccines, therapeutics, and ancillary medical supplies; and (C) expanding and enhancing capacity for manufacturing vaccines, therapeutics, and ancillary medical supplies to prevent the spread of COVID–19 and SARS–CoV–2 and . (2) Authorization of appropriations To carry out this subsection, there is authorized to be appropriated $20,000,000,000 for the period of fiscal years 2021 through 2025, to remain available until expended. (b) Report on vaccine manufacturing and administration capacity Not later than December 1, 2020, the Secretary shall submit to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor and Pensions and the Committee on Appropriations of the Senate a report detailing— (1) an assessment of the estimated supply of vaccines and ancillary medical supplies related to vaccine administration necessary to control and stop the spread of SARS–CoV–2 and COVID–19, domestically and internationally